ICICI Securities reiterates Buy on Nephrocare; target Rs 825
ICICI Securities says Nephrocare Health Services’ progress in price-sensitive markets and overseas competition supports its model, reiterating a Buy and setting a target of Rs 825.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.